“We’re excited to invest in BigOmics,” said Peter Fruhstorfer, Co-CEO of Eppendorf SE, upon signing the agreement. “With its expertise and digital know-how, the company is a perfect fit for Eppendorf and our ambition to improve work processes in the lab and set them up for the future. BigOmics and Eppendorf share the goal of accelerating digitalization in life science laboratories to make everyday research workflows simpler, safer, more efficient and faster.”

Eppendorf Innovation Company – a strategic partner for innovators in the life science market

The investment was initiated and carried out by the Eppendorf Innovation Company (EpIC), which serves as Eppendorf’s interface to innovative startups. EpIC is tasked with identifying and successfully implementing novel business models and promising partnerships for Eppendorf. To this end, EpIC is in close contact with the very dynamic international startup scene in the life science and biotechnology sector. EpIC’s scope includes areas such as liquid biopsy, innovative approaches to sample preparation for multi-omics and digital solutions for improving laboratory processes.